Incyte Corporation has presented 54-week efficacy and safety data for povorcitinib, an oral selective JAK1 inhibitor, from its pivotal Phase 3 STOP-HS program in adult patients with moderate to severe hidradenitis suppurativa, at the 2026 American Academy of Dermatology Annual Meeting. The data arrive as the drug’s New Drug Application and Marketing Authorization Application remain under active review by the U.S. Food and Drug Administration and the European Medicines Agency, respectively.

What the 54-week STOP-HS dataset adds beyond the 12-week primary endpoint

The 12-week primary endpoint data from STOP-HS1 and STOP-HS2 established that povorcitinib met the Hidradenitis Suppurativa Clinical Response threshold of at least 50% reduction in total abscess and inflammatory nodule count versus placebo. What the 54-week extension period now delivers is the more commercially and clinically consequential question: whether responses hold, deepen, or erode over time.

The headline result is that up to 71.4% of patients achieved HiSCR50 by Week 54, a meaningful improvement over the Week 12 rates and sustained across both dose levels and both studies. More analytically significant is the movement along the stringency spectrum. Up to 57% of participants achieved HiSCR75, and up to 29% reached HiSCR100, representing full clearance of the abscess and nodule burden. Clinicians tracking inflammatory dermatology have increasingly shifted attention toward these higher thresholds as the minimum credible bar for market differentiation, and the STOP-HS data position povorcitinib above what earlier-generation therapies typically delivered at comparable timepoints.

Full resolution of all three key inflammatory lesion types, designated ANdT=0, was achieved in 16.1% to 20.2% of patients at Week 54. Complete clearance of draining tunnels, historically the most treatment-resistant feature of moderate to severe HS, was not the primary objective, but the reductions reported across both doses add meaningful clinical texture. Draining tunnel count fell by up to 62% with the 75 mg dose and up to 57.7% with 45 mg. These figures are clinically relevant because draining tunnel burden drives much of the scarring and functional disability that defines disease severity for patients.

How povorcitinib’s efficacy profile compares with approved biologics in hidradenitis suppurativa

The competitive reference point for any HS regulatory submission remains adalimumab, the first approved biologic, and more recently secukinumab, which secured approval in 2023. Direct cross-trial comparisons carry the usual methodological caveats, including differences in baseline severity, prior therapy requirements, and endpoint definitions, but the HiSCR50 rate of 71.4% at Week 54 for povorcitinib compares favourably with long-term responder rates published for approved injectables. Industry observers tracking the space note that the ability to deliver sustained responses with an oral agent has been the structural gap in HS pharmacotherapy for nearly a decade, and the STOP-HS data represent the most complete attempt to date to close it.

The qualitative dimension of the dataset also matters commercially. Improvements in skin pain were reported in 40.5% to 46.8% of participants, fatigue improvements in 49.0% to 58.0%, and skin condition-related quality-of-life gains in 59.4% to 64.7%. Patient-reported outcome data of this type increasingly influence formulary access decisions, particularly in markets where payers scrutinise the real-world functional burden of dermatological conditions. The addition of fatigue and pain data is also strategically significant because it speaks to the systemic inflammatory load of HS, which is frequently underweighted in clinical trial primary endpoint framing.

What the 54-week safety profile reveals about JAK1 selectivity in a chronic inflammatory setting

The safety narrative is where regulators and prescribers will scrutinise most closely, given the class-wide questions that have followed JAK inhibitors across indications since the cardiovascular safety signals identified in rheumatoid arthritis trials. Through Week 54, treatment-emergent adverse events were reported in 76.2% to 83.4% of patients, with the most frequent events being acne, nasopharyngitis, and upper respiratory tract infections. The incidence of serious adverse events ranged from 3.7% to 6.4%, and events leading to discontinuation were low at 6.1% to 9.4%.

Adverse events of special interest, including herpes zoster, serious infections, opportunistic infections, malignancies, and thromboembolic events, each remained below 2.3%. One major adverse cardiovascular event was reported and characterised as unrelated to study drug by Incyte. The total number of major cardiovascular and deep vein thrombosis or pulmonary embolism events was four across both studies through 54 weeks. Regulatory watchers suggest that this signal pattern will be closely assessed by the FDA in the context of the agency’s prior boxed warning decisions for less selective JAK inhibitors in autoimmune indications, and whether the JAK1 selectivity profile of povorcitinib is sufficient to support a cleaner label.

The HS patient population presents a specific complicating factor in cardiovascular safety interpretation. Published literature consistently documents elevated rates of metabolic comorbidities, obesity, and systemic inflammation in moderate to severe HS patients, independent of treatment. Incyte has noted that the cardiovascular event rate observed through Week 54 is consistent with published background rates in the HS population, a framing that regulators will assess against the controlled and uncontrolled arms of the STOP-HS program separately.

Whether the regulatory pathway for povorcitinib in HS faces any remaining structural uncertainty

Both the NDA in the United States and the MAA in Europe are under active review, placing povorcitinib on a potential approval trajectory that would make it the first oral therapy for moderate to severe HS in either jurisdiction. The primary regulatory question that persists is not efficacy, where the dataset is substantially complete, but labelling. The FDA’s approach to JAK inhibitor labelling has evolved since 2021, when the agency required expanded safety warnings across the class following the ORAL Surveillance study results in rheumatoid arthritis. The question for povorcitinib is the degree to which JAK1 selectivity, which was the design rationale for the molecule, translates into a differentiated label versus a class-wide imposition of warnings.

The EMA’s posture on JAK inhibitor safety has been similarly precautionary, and the parallel review adds complexity around how risk minimisation measures may differ between the two jurisdictions. Clinicians tracking the dermatology regulatory space suggest that the outcome in the U.S. will likely set a directional benchmark for the European assessment, and that both agencies are likely to request clarification on the cardiovascular monitoring requirements that should accompany any label.

What the pipeline depth behind STOP-HS signals about Incyte’s inflammation and autoimmunity strategy

The STOP-HS data sit within a broader povorcitinib development programme that extends to nonsegmental vitiligo and prurigo nodularis, with Phase 3 topline data expected in mid-2026 and the fourth quarter of 2026, respectively. A Phase 2 trial in moderate to severe asthma is also ongoing. The strategic logic of the platform is the applicability of JAK1 selectivity across JAK-STAT-driven inflammatory conditions, each requiring individual clinical validation but sharing a common mechanistic rationale.

If povorcitinib secures approval in HS, the commercial infrastructure established for that launch creates an efficiency advantage for any subsequent approvals in vitiligo or prurigo nodularis, both of which involve dermatology prescribers and patient populations with overlapping demographic profiles. Industry observers note that the concentration of Phase 3 programmes across JAK-STAT conditions reflects Incyte’s effort to construct a defensible inflammatory dermatology franchise, positioning the company against both established biologics manufacturers and the growing cohort of companies developing selective cytokine inhibitors for skin diseases.

The unresolved questions ahead of any regulatory decision include the precise label framing, the reimbursement positioning relative to injectable biologics already on formulary, and whether the response rates in real-world HS populations, which typically carry greater comorbidity burden than clinical trial cohorts, will replicate the STOP-HS outcomes. Those questions will define the commercial ceiling of the programme as much as any regulatory outcome.

  American Academy of Dermatology, EMA, FDA, hidradenitis suppurativa, HiSCR50, INCB54707, Incyte, JAK1 inhibitor, MAA, NDA, povorcitinib, STOP-HS